3McGlynn LM,Kirkegaard T,Edwards J,et al.Ras/Raf-1/ MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients[J].Clin Cancer Res,2009,15 (4):1487-1495.
4Narita D,Seclaman E,Ursoniu S,et al.Expression of CCL18 and interleukin-6 in the plasma of breast cancer patients as compared with benign tumor patients and healthy controls[J].Rom J Morphol Embryol,2011,52 (4):1261-1267.
5Yamashita-Kashima Y,Iijima S,Yorozu K,et al.Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models[J].Clin Cancer Res,2011,17 (15):5060-5070.
6Milanezi F,Carvalho S,Schmitt FC.EGFR/HER2 in breast cancer:a biological approach for molecular diagnosis and therapy[J].Expert Rev Mol Diagn,2008,8 (4):417-434.
7Bender LM,Nahta R.Her2 cross talk and therapeutic resistance in breast cancer[J].Front Biosci,2008,13:3906-3912.
8Verma S,Miles D,Gianni L,et al.Trastuzumab emtansine for HER2-positive advanced breast cancer[J].N Engl J Med,2012,367 (19):1783-1791.
9Rowe DL,Ozbay T,Bender LM,et al.Nordihydroguaiaretic acid,a cytotoxic insulin-like growth factor-Ⅰ receptor/HER2 inhibitor in trastuzumab-resistant breast cancer[J].Mol Cancer Ther,2008,7 (7):1900-1908.
10Portera CC,Walshe JM,Rosing DR,et al.Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with[corrected]human epidermal growth factor receptor 2-positive metastatic breast cancer[J].Clin Cancer Res,2008,14(9):2710-2716.
